CA3023687A1 - Compositions multiparticulaires de l-carnitine et de nootropes, et methodes associees - Google Patents

Compositions multiparticulaires de l-carnitine et de nootropes, et methodes associees Download PDF

Info

Publication number
CA3023687A1
CA3023687A1 CA3023687A CA3023687A CA3023687A1 CA 3023687 A1 CA3023687 A1 CA 3023687A1 CA 3023687 A CA3023687 A CA 3023687A CA 3023687 A CA3023687 A CA 3023687A CA 3023687 A1 CA3023687 A1 CA 3023687A1
Authority
CA
Canada
Prior art keywords
carnitine
composition
core
nootropic substance
nootropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3023687A
Other languages
English (en)
Inventor
Syed M. Shah
Christopher Diorio
Daniel HASSAN
Noreen HASSAN
Fred Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Physicians Seal LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physicians Seal LLC filed Critical Physicians Seal LLC
Publication of CA3023687A1 publication Critical patent/CA3023687A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a trait à des compositions multiparticulaires de L-carnitine et de nootropes, et des méthodes associées. Une composition comprend une forme posologique pharmaceutique thérapeutiquement efficace comprenant un grand nombre de particules individuelles. Les particules individuelles comportent respectivement : un noyau comprenant une combinaison de principes actifs de L-carnitine et d'une substance nootropique, et un polymère de contrôle de la libération en surface du noyau qui empêche nettement la libération des principes actifs dans le milieu acide de l'estomac et permet la libération des principe actifs dans un environnement à pH intestinal. La composition peut être utilisée pour traiter des affections associées à une diminution de la quantité de L-carnitine dans le corps et/ou une déficience cognitive.
CA3023687A 2016-05-06 2017-05-04 Compositions multiparticulaires de l-carnitine et de nootropes, et methodes associees Abandoned CA3023687A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332683P 2016-05-06 2016-05-06
US62/332,683 2016-05-06
PCT/US2017/031022 WO2017192828A1 (fr) 2016-05-06 2017-05-04 Compositions multiparticulaires de l-carnitine et de nootropes, et méthodes associées

Publications (1)

Publication Number Publication Date
CA3023687A1 true CA3023687A1 (fr) 2017-11-09

Family

ID=60203745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023687A Abandoned CA3023687A1 (fr) 2016-05-06 2017-05-04 Compositions multiparticulaires de l-carnitine et de nootropes, et methodes associees

Country Status (3)

Country Link
CA (1) CA3023687A1 (fr)
MX (2) MX2018013567A (fr)
WO (1) WO2017192828A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008134143A (ru) * 2008-08-21 2010-02-27 Тимофей Георгиевич Кожока (RU) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
US8828426B2 (en) * 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods

Also Published As

Publication number Publication date
MX2018013567A (es) 2019-01-31
WO2017192828A1 (fr) 2017-11-09
MX2021012580A (es) 2021-11-12

Similar Documents

Publication Publication Date Title
US11896721B2 (en) Multiparticulate L-carnitine compositions and related methods
KR101157220B1 (ko) 리팍시민을 포함하는 위내성 약학적 제제
US6726927B2 (en) Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole
US11779547B2 (en) Multiparticulate L-menthol formulations and related methods
SK18832000A3 (sk) Entericky potiahnutá farmaceutická tableta a spôsob jej prípravy
US20120315337A1 (en) Multiparticulate 5-htp compositions and related methods
AU5793799A (en) Omeprazole formulation
AT6311U1 (de) Pharmazeutische zusammensetzung mit magensaftresistentem überzug und methode zur herstellung
HU186078B (en) Process for producing pharmaceutical compositions for peroral application containing dipyridamol
US20130004563A1 (en) Multiparticulate s-adenosylmethionine compositions and related methods
EP1667660A2 (fr) Preparations multiparticulaires de pantoprazole
WO2006002032A1 (fr) Divalproex de sodium neutralise a liberation prolongee
WO2007022944A1 (fr) Préparation pharmaceutique solide comprenant de la 1-(4-chloroanilino)-4-(4-pyridylméthyl)phtalazine et un modificateur de ph
EP1267840A1 (fr) Particules granulees a masquage de gout
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
US20170231940A1 (en) Multiparticulate L-Carnitine And Nootropic Compositions And Related Methods
CA2984235C (fr) Composition pharmaceutique a liberation prolongee contenant de la rivastigmine
US20190125792A1 (en) Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
CA3023687A1 (fr) Compositions multiparticulaires de l-carnitine et de nootropes, et methodes associees
MXPA00010963A (en) Enteric coated pharmaceutical composition and method of manufacturing
NZ510231A (en) Omeprazole formulation comprising an alkaline core and an enteric coating

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

EEER Examination request

Effective date: 20220504

FZDE Discontinued

Effective date: 20231106